Apyx Medical Corporation (APYX)
NASDAQ: APYX · IEX Real-Time Price · USD
1.320
-0.060 (-4.35%)
At close: Apr 19, 2024, 4:00 PM
1.370
+0.050 (3.79%)
After-hours: Apr 19, 2024, 5:15 PM EDT

Company Description

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally.

The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM).

It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.

The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market.

It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories.

The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019.

Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Apyx Medical Corporation
Apyx Medical logo
Country United States
IPO Date Jan 1, 1987
Industry Medical Devices
Sector Healthcare
Employees 252
CEO Charles D. Goodwin II

Contact Details

Address:
5115 Ulmerton Road
Clearwater, Florida 33760
United States
Phone (727) 384-2323
Website apyxmedical.com

Stock Details

Ticker Symbol APYX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000719135
CUSIP Number 03837C106
ISIN Number US03837C1062
Employer ID 11-2644611
SIC Code 3841

Key Executives

Name Position
Charles D. Goodwin II President, Chief Executive Officer and Director
Matthew C. Hill CPA Chief Financial Officer, Treasurer and Secretary
Moshe Citronowicz Senior Vice President
Todd Hornsby Executive Vice President

Latest SEC Filings

Date Type Title
Apr 5, 2024 SC 13D General statement of acquisition of beneficial ownership
Apr 1, 2024 SC 13D General statement of acquisition of beneficial ownership
Mar 25, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 21, 2024 10-K Annual Report
Mar 21, 2024 8-K Current Report
Feb 21, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals